Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJul 12, 2026
DataAggregated Company Financials
Companies65
  • 7D0.3%
  • 3M12.1%
  • 1Y16.2%
  • YTD-4.4%

The Life Sciences industry has been flat over the last week, but West Pharmaceutical Services has lost 3.3%. The past year has been better, since the industry has gained 16% in that time. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 12 Jul 2026US$650.5bUS$151.2bUS$13.6b45.3x47.7x4.3x
Tue, 09 Jun 2026US$586.3bUS$150.6bUS$13.8b38.4x42.6x3.9x
Thu, 07 May 2026US$555.7bUS$150.2bUS$14.0b33.7x39.7x3.7x
Sat, 04 Apr 2026US$561.8bUS$147.8bUS$14.1b37.2x39.9x3.8x
Mon, 02 Mar 2026US$599.3bUS$147.9bUS$14.0b35.2x42.9x4.1x
Wed, 28 Jan 2026US$696.9bUS$145.9bUS$12.4b35.8x56.3x4.8x
Fri, 26 Dec 2025US$664.7bUS$145.8bUS$12.5b35.3x53.3x4.6x
Sun, 23 Nov 2025US$666.0bUS$145.6bUS$12.4b36.2x53.8x4.6x
Tue, 21 Oct 2025US$636.0bUS$144.3bUS$14.6b32.5x43.7x4.4x
Thu, 18 Sep 2025US$571.0bUS$144.3bUS$14.6b29.7x39.2x4x
Sat, 16 Aug 2025US$580.5bUS$144.2bUS$14.5b29x40.1x4x
Mon, 14 Jul 2025US$551.9bUS$142.9bUS$9.1b36.9x60.5x3.9x
Wed, 11 Jun 2025US$525.9bUS$142.9bUS$9.2b36.7x57.4x3.7x
Fri, 09 May 2025US$511.1bUS$142.7bUS$9.6b35x53.2x3.6x
Sun, 06 Apr 2025US$509.0bUS$142.5bUS$9.9b33.4x51.2x3.6x
Tue, 04 Mar 2025US$605.1bUS$143.0bUS$9.7b37.7x62.4x4.2x
Thu, 30 Jan 2025US$705.6bUS$142.4bUS$10.2b41.1x69.1x5x
Sat, 28 Dec 2024US$659.4bUS$142.4bUS$10.2b44.7x64.5x4.6x
Mon, 25 Nov 2024US$656.8bUS$142.4bUS$10.4b44.1x63.4x4.6x
Wed, 23 Oct 2024US$727.8bUS$140.7bUS$8.2b36.7x88.7x5.2x
Fri, 20 Sep 2024US$744.1bUS$141.8bUS$8.5b38.1x87.6x5.2x
Sun, 18 Aug 2024US$738.6bUS$141.5bUS$8.4b38.8x88.3x5.2x
Tue, 16 Jul 2024US$685.9bUS$141.2bUS$12.2b41x56.2x4.9x
Thu, 13 Jun 2024US$706.7bUS$141.3bUS$12.2b37.6x58x5x
Sat, 11 May 2024US$719.0bUS$141.5bUS$12.7b38.6x56.8x5.1x
Mon, 08 Apr 2024US$727.9bUS$142.1bUS$12.8b43.1x56.9x5.1x
Wed, 06 Mar 2024US$747.1bUS$142.1bUS$12.8b44.3x58.2x5.3x
Fri, 02 Feb 2024US$710.9bUS$147.6bUS$12.5b38.7x56.8x4.8x
Sun, 31 Dec 2023US$700.9bUS$153.8bUS$14.2b37.8x49.2x4.6x
Tue, 28 Nov 2023US$642.9bUS$153.8bUS$14.0b34.5x45.9x4.2x
Thu, 26 Oct 2023US$578.1bUS$153.9bUS$10.8b29.9x53.6x3.8x
Sat, 23 Sep 2023US$670.2bUS$154.6bUS$11.2b31.2x59.8x4.3x
Mon, 21 Aug 2023US$702.8bUS$154.6bUS$11.2b32.5x62.7x4.5x
Wed, 19 Jul 2023US$703.7bUS$155.5bUS$12.7b29.6x55.5x4.5x
Price to Earnings Ratio

55.5x


Total Market Cap: US$703.7bTotal Earnings: US$12.7bTotal Revenue: US$155.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 47.7x which is lower than its 3-year average PE of 56.0x.
  • The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 2.5% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.81%
Healthcare-1.49%
Life Sciences0.27%
Clinical Research and Equipment0.27%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$527.050.7%
+US$1.3b		21.2%PE28.6x
A Agilent TechnologiesUS$134.292.8%
+US$1.0b		8.9%PE26.8x
DHR DanaherUS$199.050.6%
+US$792.7m		-2.8%PE38.3x
TXG 10x GenomicsUS$42.739.5%
+US$472.3m		233.8%PS8.5x
QGEN QiagenUS$41.513.5%
+US$291.6m		-18.1%PE21.3x

Latest News

ILMN
US$190.20
Illumina
7D
0.8%
1Y
91.6%
DHR
US$199.05
Danaher
7D
0.6%
1Y
-2.8%
Seeking Alpha • Jul 10

Danaher Is Getting Better, But The Stock Still Isn't Cheap

Summary Danaher Corporation remains slightly overvalued despite recent share price declines and ongoing operational improvements. Q1/26 results showed modest core revenue growth of 0.5%, with bioprocessing as the primary growth driver and diagnostics continuing to struggle. Current valuation multiples—37x earnings and 25.8x FCF—exceed long-term averages, with intrinsic value estimated at $172.91 per share. I maintain a cautious stance and rate DHR as a hold, citing uncertain long-term double-digit growth prospects and reliance on improved segment performance. Read the full article on Seeking Alpha
A
US$134.29
Agilent Technologies
7D
2.8%
1Y
8.9%
BRKR
US$60.06
Bruker
7D
-2.6%
1Y
37.2%
Narrative Update • Jul 10

BRKR: Diagnostics Portfolio Momentum Will Counter Valuation And Execution Uncertainty

The analyst fair value estimate for Bruker has been raised from $53.25 to $56.00 after analysts responded to a series of higher Street price targets and updated models across diagnostics and life sciences tools coverage. Analyst Commentary Recent Street research on Bruker shows a mix of optimism and caution, with several firms updating price targets and ratings as they refresh models across diagnostics and life sciences tools coverage.
QGEN
US$41.51
Qiagen
7D
3.5%
1Y
-18.1%
TEM
US$58.23
Tempus AI
7D
-3.4%
1Y
2.4%
TXG
US$42.73
10x Genomics
7D
9.5%
1Y
233.8%
Narrative Update • Jul 09

TXG: Cancer Collaboration And Spatial Rollout Will Support More Constructive Outlook

Analysts have lifted the 10x Genomics fair value estimate from $40.00 to $45.00, reflecting higher Street price targets, including recent moves to $37 at Morgan Stanley, $40 at Barclays, and $45 at Citi. These changes are supported by updated earnings models and growing interest in life science tools.
ABCL
US$6.80
AbCellera Biologics
7D
-16.2%
1Y
69.6%
Narrative Update • Jul 09

ABCL: Jazz Deal And Menopause Program Will Support A Stronger Outlook

The analyst fair value estimate for AbCellera Biologics has been raised from $12.00 to $13.00 as analysts point to the new Jazz Pharmaceuticals agreement, recent rating upgrades, and a more constructive view on the company's long term earnings potential, despite lower modeled revenue growth and a higher future P/E assumption. Analyst Commentary Bullish analysts covering AbCellera Biologics are highlighting the recent agreement with Jazz Pharmaceuticals as an important proof point for the company’s partnership model and revenue opportunity.
TMO
US$527.05
Thermo Fisher Scientific
7D
0.7%
1Y
21.2%
Narrative Update • Jul 09

TMO: AI Tools And Biopharma Collaborations Will Drive Future Performance

Thermo Fisher Scientific's analyst price target has been trimmed slightly, with the fair value estimate moving from $611.56 to about $590.77 as analysts factor in a modestly higher discount rate and slightly softer long term revenue growth and margin assumptions, alongside a mix of cautious sector views and continued confidence in the company's role across life science tools and diagnostics. Analyst Commentary Recent research on Thermo Fisher Scientific shows a mix of optimism and caution, with several firms updating price targets, ratings, and sector views as they reassess growth drivers, capital spending trends, and long term organic growth expectations.
ICLR
US$167.72
ICON
7D
-3.1%
1Y
11.4%
ALMR
US$28.42
Alamar Biosciences
7D
9.6%
1Y
n/a
WST
US$353.71
West Pharmaceutical Services
7D
-3.3%
1Y
55.7%
MTD
US$1,296.17
Mettler-Toledo International
7D
-0.9%
1Y
5.9%
WAT
US$376.43
Waters
7D
-0.8%
1Y
6.7%
Narrative Update • Jul 02

WAT: AI Immune Profiling Partnership And Biotech Tools Will Support Steady Profitability

Analysts have nudged their price target on Waters higher to about $402 from roughly $393, citing updated assumptions that include an adjusted discount rate of 8.24%, revenue growth expectations of 27.01%, a profit margin estimate of 16.78%, and a forward P/E of 47.17x. What’s in the News for Waters Waters and IMU Biosciences formed a partnership that combines Waters Biosciences flow cytometry and single cell technologies with IMU’s AI and machine learning platform to support high definition immune profiling across discovery, translational, and clinical research.
MEDP
US$538.23
Medpace Holdings
7D
-3.5%
1Y
66.4%
Narrative Update • Jun 29

MEDP: Slower Revenue Outlook And Lower P/E Assumptions Will Pressure Expectations

Analysts have trimmed their price targets on Medpace Holdings, with the updated fair value estimate moving from $500.08 to $443.50 as they factor in slightly higher discount rates, more moderate revenue growth assumptions, a marginally lower profit margin outlook, and a modestly reduced future P/E multiple. Analyst Commentary Recent research updates on Medpace Holdings point to a more cautious stance on valuation, with several firms trimming their price targets even as they recognize the company’s execution strengths and long-term opportunities.
STVN
US$19.59
Stevanato Group
7D
3.1%
1Y
-22.3%
Narrative Update • Jun 15

STVN: GLP-1 Exposure And Biologics Focus Will Support Future Earnings Power

Analysts have trimmed their price target on Stevanato Group to about $24.39 from $24.81, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E. Recent Street research has also highlighted the company’s exposure to biologics and GLP-1 related demand.